Merck
CN
  • Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.

Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.

PloS one (2014-05-23)
Preethi S Nair, Shrimati D Shetty, S Chandrakala, Kanjaksha Ghosh
摘要

Despite increased awareness and diagnostic facilities, 70-80% of the haemophilia A (HA) patients still remain undiagnosed in India. Very little data is available on prevalent mutations in HA from this country. We report fifty mutations in seventy one Indian HA patients, of which twenty were novel. Ten novel missense mutations [p.Leu11Pro (p.Leu-8Pro), p.Tyr155Ser (p.Tyr136Ser), p.Ile405Thr (p.Ile386Thr), p.Gly582Val (p.Gly563Val) p.Thr696Ile (p.Thr677Ile), p.Tyr737Cys (p.Tyr718Cys), p.Pro1999Arg (p.Pro1980Arg), p.Ser2082Thr (p.Ser2063Thr), p.Leu2197Trp (p.Leu2178Trp), p.Asp2317Glu (p.Asp2298Glu)] two nonsense [p.Lys396* (p.Lys377*), p.Ser2205* (p.Ser2186*)], one insertion [p.Glu1268_Asp1269ins (p.Glu1249_Asp1250)] and seven deletions [p.Leu882del (p.Leu863del), p.Met701del (p.Met682del), p.Leu1223del (p.Leu1204del), p.Trp1961_Tyr1962del (p.Trp1942_Tyr1943del) p.Glu1988del (p.Glu1969del), p.His1841del (p.His1822del), p.Ser2205del (p.Ser2186del)] were identified. Double mutations (p.Asp2317Glu; p.Thr696Ile) were observed in a moderate HA case. Mutations [p. Arg612Cys (p.Arg593Cys), p.Arg2326Gln (p.Arg2307Gln)] known to be predisposing to inhibitors to factor VIII (FVIII) were identified in two patients. 4.6% of the cases were found to be cross reacting material positive (CRM+ve). A wide heterogeneity in the nature of mutations was seen in the present study which has been successfully used for carrier detection and antenatal diagnosis in 10 families affected with severe to moderate HA.

材料
货号
品牌
产品描述

Sigma-Aldrich
乙二醇, anhydrous, 99.8%
Sigma-Aldrich
乙二醇, ReagentPlus®, ≥99%
Supelco
乙二醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
丙烯酰胺, suitable for electrophoresis, ≥99%
Sigma-Aldrich
甲酰胺, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
甲酰胺, ≥99.5% (GC), BioReagent, for molecular biology
Sigma-Aldrich
哌嗪, ReagentPlus®, 99%
Sigma-Aldrich
溴化乙啶 溶液, BioReagent, for molecular biology, 10 mg/mL in H2O
USP
乙二醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲酰胺, BioUltra, for molecular biology, ≥99.5% (T)
Sigma-Aldrich
丙烯酰胺, for molecular biology, ≥99% (HPLC)
Supelco
乙二醇, analytical standard
Sigma-Aldrich
丙烯酰胺 溶液, 40%, suitable for electrophoresis, sterile-filtered
Sigma-Aldrich
丙烯酰胺, suitable for electrophoresis, ≥99% (HPLC), powder
Sigma-Aldrich
溴化乙锭, BioReagent, for molecular biology, powder
Sigma-Aldrich
甲酰胺, ACS reagent, ≥99.5%
Sigma-Aldrich
溴化乙啶 溶液, BioReagent, for molecular biology, 500 μg/mL in H2O
Sigma-Aldrich
乙二醇, spectrophotometric grade, ≥99%
Sigma-Aldrich
溴化乙锭, ~95% (HPLC)
Supelco
丙烯酰胺, analytical standard
Sigma-Aldrich
哌嗪, BioUltra, anhydrous, ≥99.0% (T)
Sigma-Aldrich
乙二醇, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
丙烯酰胺, purum, ≥98.0% (GC)
Sigma-Aldrich
甲酰胺, spectrophotometric grade, ≥99%
Supelco
丙烯酰胺 溶液, 40% in H2O, for molecular biology
Sigma-Aldrich
丙烯酰胺, for Northern and Southern blotting, powder blend
Sigma-Aldrich
乙二醇 溶液
Sigma-Aldrich
溴化乙啶 溶液, for fluorescence, ~1% in H2O
Supelco
丙烯酰胺, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
乙二醇 溶液, NMR reference standard, 80% in DMSO-d6 (99.9 atom % D), NMR tube size 5 mm × 8 in.